The Annual General Meeting of Biovitrum resolved on 28 April 2009 to
issue 231,585 series C shares to secure that the company can fulfill
its commitment according to the performance based, long-term share
program for 2009 ("Share Program 2009"). Furthermore, the Annual
General Meeting resolved to authorize the board of directors to
repurchase all issued series C shares for a price per share
corresponding to the quota value of the Biovitrum share, i.e. in
total SEK 127,069.9623. The series C shares will thereafter be
converted to common shares in the number that is required to secure
delivery under the Share Program 2009.
The board of directors of Biovitrum has resolved to utilize the
authorization for this purpose and to immediately repurchase all
issued series C shares in accordance with the resolution by the
Annual General Meeting on 28 April 2009. Biovitrum currently holds
284,000 own series C shares which were issued during 2008.
For further information, please contact:
Biovitrum AB (publ)
Martin Nicklasson, CEO
Phone: +46 8 697 20 00
Göran Arvidson, CFO
Phone: +46 70 633 30 42
Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
[email protected]
About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
malabsorption. Biovitrum has revenues of approximately SEK 1.2
billion and approximately 400 employees (prior to the Transaction).
Biovitrum's head office is located in Sweden and the share is listed
on the NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com.
The above information has been made public in accordance with the
Securities Market Act and/or the Financial Instruments Trading Act.
The information was published at 8:30 CET on December 3, 2009.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.